Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living‐donor liver transplantation: A Japanese multicenter experience

This study aimed to clarify the efficacy and safety of simeprevir, a second‐generation NS3/4A inhibitor, with peginterferon and ribavirin for recurrent hepatitis C after liver transplantation.

[1]  E. Schiff,et al.  Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. , 2015, Gastroenterology.

[2]  Aasld Idsa Hcv Guidance Panel.  Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus , 2015, Hepatology.

[3]  S. Pungpapong,et al.  Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant , 2015, Hepatology.

[4]  M. Kurosaki,et al.  Use of simeprevir following pre‐emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12‐week pilot study , 2015, Journal of hepato-biliary-pancreatic sciences.

[5]  S. Uemoto,et al.  Fluctuations in the concentration/dose ratio of calcineurin inhibitors after simeprevir administration in patients with recurrent hepatitis C after liver transplantation , 2015, Transplant international : official journal of the European Society for Organ Transplantation.

[6]  M. Manns,et al.  Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. , 2015, Gastroenterology.

[7]  X. Forns,et al.  An interferon-free antiviral regimen for HCV after liver transplantation. , 2014, The New England journal of medicine.

[8]  G. Everson,et al.  A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. , 2014, Journal of hepatology.

[9]  M. Bilodeau,et al.  Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience. , 2014, Annals of hepatology.

[10]  M. Manns,et al.  Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial , 2014, The Lancet.

[11]  Oliver Lenz,et al.  Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial , 2014, The Lancet.

[12]  N. Hayashi,et al.  Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. , 2014, Journal of hepatology.

[13]  X. Forns,et al.  Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. , 2014, Gastroenterology.

[14]  N. Hayashi,et al.  Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies , 2014, Journal of Gastroenterology.

[15]  D. Samuel,et al.  Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. , 2014, Journal of hepatology.

[16]  S. Pungpapong,et al.  Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[17]  R. Fontana,et al.  Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  E. Wang,et al.  Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. , 2012, Gastroenterology.

[19]  N. Hayashi,et al.  Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. , 2012, Journal of hepatology.

[20]  V. Garg,et al.  Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus , 2011, Hepatology.

[21]  Geoffrey Dusheiko,et al.  Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.

[22]  O. Weiland,et al.  Telaprevir for retreatment of HCV infection. , 2011, The New England journal of medicine.

[23]  H. Nomura,et al.  The rs8099917 Polymorphism, When Determined by a Suitable Genotyping Method, Is a Better Predictor for Response to Pegylated Alpha Interferon/Ribavirin Therapy in Japanese Patients than Other Single Nucleotide Polymorphisms Associated with Interleukin-28B , 2011, Journal of Clinical Microbiology.

[24]  F. Poordad,et al.  Treatment of hepatitis C , 2003 .

[25]  H. Nomura,et al.  The rs 8099917 Polymorphism , When Determined by a Suitable Genotyping Method , Is a Better Predictor for Response to Pegylated Alpha Interferon / Ribavirin Therapy in Japanese Patients than Other Single Nucleotide Polymorphisms Associated with Interleukin-28 B † , 2011 .

[26]  J J Fung,et al.  Liver Transplantation in the United States, 1999–2008 , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  F. Gordon,et al.  Treatment of hepatitis C in liver transplant recipients , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[28]  N. Terrault.  Hepatitis C therapy before and after liver transplantation , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[29]  M. Berenguer.  Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. , 2008, Journal of hepatology.

[30]  A. Sanyal,et al.  A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[31]  A. Dhillon,et al.  Liver transplantation for HCV cirrhosis: Improved survival in recent years and increased severity of recurrent disease in female recipients: Results of a long term retrospective study , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[32]  J. Dumortier,et al.  Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: A retrospective analysis of 939 liver biopsies in a single center , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[33]  P. Terasaki,et al.  Liver transplantation in the United States. , 2005, Clinical transplants.

[34]  U. Neumann,et al.  Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. , 2004, Journal of hepatology.

[35]  J. Berlin,et al.  The association between hepatitis C infection and survival after orthotopic liver transplantation. , 2002, Gastroenterology.

[36]  L. Ferrell,et al.  HCV-related fibrosis progression following liver transplantation: increase in recent years. , 2000, Journal of hepatology.

[37]  G. Alexander,et al.  European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. , 1999, Gastroenterology.

[38]  J. Córdoba,et al.  High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes , 1999, Hepatology.

[39]  M. Mizokami,et al.  New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a , 1997, Journal of clinical microbiology.

[40]  T E Starzl,et al.  Liver transplantation. , 1967, Bulletin de la Societe internationale de chirurgie.